Drug Trial Radar · NCT07500207
A Phase III Clinical Trial on Immunogenicity and Safety of Lyophilized Rabies Vaccine for Human Use (Human Diploid Cell)
Last checked: Nov 20, 2026Latest source record: Mar 30, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Enrolling by invitation
Enrollment
3,000
Planned (sponsor's estimate)
Start
Mar 4, 2026
Primary completion
May 25, 2026
Study completion Mar 25, 2027
Sponsor
- Lead sponsor
- Changchun BCHT Biotechnology Co.Industry
- Sponsor type
- Industry
- First posted
- Mar 30, 2026
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Single (participant)
- Primary purpose
- Prevention
- FDA-regulated drug
- No
- Who can join
- All sexes, from 10 years, up to 60 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
Neutralizing antibody seroconversion rate and geometric mean concentration in seronegative participants of each group at 14 days after the first dose of immunization. The seroconversion rate of neutralizing antibodies 42 days after the first dose among seronegative participants before vaccination in each group
Conditions
- Rabies Prevention
Interventions
Experimental Lyophilized Human Rabies Vaccine (Human Diploid Cell)Biological
Dosage schedule: Five-dose regimen: one dose on days 0, 3, 7, 14, and 28 respectively; 2-1-1 regimen: administration on days 0, 7, and 21, with 2 doses on day 0 and 1 dose on each of the other days; Simplified four-dose regimen: one dose on days 0, 3, 7, and 14, or one dose on days 0, 3, 7, and 28 respectively.
approved Rabies vaccineBiological
One dose shall be administered on days 0, 3, 7, 14, and 28 respectively.
Primary outcomes
What the sponsor says the trial is designed to measure.
- neutralizing antibodies after the first doseTime frame: 14 days and 42 day after the first dose
Locations
1 site in 1 country. Site status is shown where the registry gives one.
sichuan CDC
Neijiang, Sichuan, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.